Zyversa Therapeutics, INC 8-K filings

ZyVersa Therapeutics, Inc. announced its common stock has ceased trading on the OTCQB Venture Market and commenced trading on the OTC Pink Limited Market, effective July 16, 2026.

ZyVersa Therapeutics is implementing cost-cutting measures and exploring strategic options, including potential divestitures and headcount reductions, as it seeks to raise capital and ensure continued operations.

ZyVersa Therapeutics, Inc. has raised $1 million through a private placement of convertible promissory notes and common stock purchase warrants to accredited investors for working capital.

Robert G. Finizio has resigned from ZyVersa Therapeutics' Board of Directors, effective immediately, citing personal reasons.

ZyVersa Therapeutics reported a significant increase in net losses for Q3 2025, primarily due to an $18.6 million R&D impairment, and indicated an urgent need for additional financing to sustain operations.

Dr. Pablo Guzman has resigned from his roles as Chief Medical Officer and Senior Vice President of Medical Affairs at ZyVersa Therapeutics, Inc., effective October 10, 2025.

ZyVersa Therapeutics, Inc. announced its common stock will be delisted from the Nasdaq Stock Market due to failure to meet minimum bid price requirements.

ZyVersa Therapeutics, Inc. announced its common stock has been approved for quotation on the OTCQB Venture Market, with trading expected to commence on July 28, 2025.

ZyVersa Therapeutics, Inc. received a final determination from Nasdaq to deny its appeal for continued listing, leading to a suspension of trading and planned delisting, with the company intending to move to the Pink Limited Market.

ZyVersa Therapeutics, Inc. has entered into an inducement offer to accelerate the exercise of existing warrants at a reduced price, generating approximately $2.05 million in gross proceeds and issuing new Series A-4 warrants.

ZyVersa Therapeutics, Inc. has entered into an Equity Purchase Agreement with Williamsburg Venture Holdings, LLC for up to $10 million in common stock sales to fund the clinical development of its Cholesterol Efflux MediatorTM VAR 200 for kidney diseases.

ZyVersa Therapeutics, Inc. announced that its stockholders approved an amendment to its equity incentive plan, increasing shares available for awards, and authorized the issuance of shares related to recent warrant exercises at its 2025 Annual Meeting.

Zyversa Therapeutics, Inc. has received a delisting notice from Nasdaq due to its common stock trading below $1.00 for 30 consecutive business days and is ineligible for the standard cure period, prompting the company to appeal the decision.

ZyVersa Therapeutics announces the resignation of Marcum LLP as its independent auditor and the engagement of CBIZ CPAs, effective April 7, 2025, following Marcum's acquisition by CBIZ CPAs.

ZyVersa Therapeutics raises $2 million through a private placement of pre-funded and common stock purchase warrants to enhance its working capital.

ZyVersa Therapeutics reported its third quarter 2024 financial results, highlighted progress in its clinical programs, and announced the formation of a new Scientific Advisory Board.

ZyVersa Therapeutics is offering new warrants to existing warrant holders to encourage them to exercise their current warrants at a reduced price, potentially raising $1.7 million.

ZyVersa Therapeutics' stockholders approved an increase in shares reserved for issuance under the 2022 Omnibus Equity Incentive Plan and the issuance of shares upon exercise of certain warrants at their 2024 annual meeting.

Zyversa Therapeutics has entered into a sales agreement to offer and sell up to $1,397,396 of its common stock through an at-the-market offering.

ZyVersa Therapeutics is offering new warrants to a holder of existing warrants in exchange for exercising those warrants at a reduced price, aiming to raise approximately $830,000.

ZyVersa Therapeutics enacted a 1-for-10 reverse stock split of its common stock, effective April 25, 2024, to maintain Nasdaq listing compliance.

ZyVersa Therapeutics' stockholders approved a reverse stock split at a ratio of 1-for-10, set to take effect on April 25, 2024.

ZyVersa Therapeutics received a letter of reprimand from Nasdaq for a non-compliant 2023 offering and is planning a reverse stock split to address a minimum bid price deficiency.

ZyVersa Therapeutics will transfer its stock listing from the Nasdaq Global Market to the Nasdaq Capital Market effective March 1, 2024, resolving a prior MVPHS deficiency.